RGNX
Regenxbio Inc

2,535
Mkt Cap
$688M
Volume
175,289.00
52W High
$13.93
52W Low
$5.04
PE Ratio
-3.93
RGNX Fundamentals
Price
$13.50
Prev Close
$13.62
Open
$13.57
50D MA
$10.15
Beta
1.61
Avg. Volume
487,646.38
EPS (Annual)
-$4.59
P/B
3.21
Rev/Employee
$236,056.66
Loading...
Loading...
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
353

Frequently Asked Questions

What is Market Cap of Regenxbio Inc?
What is the 52-week high for Regenxbio Inc?
What is the 52-week low for Regenxbio Inc?
What is Regenxbio Inc stock price today?
What was Regenxbio Inc stock price yesterday?
What is the PE ratio of Regenxbio Inc?
What is the Price-to-Book ratio of Regenxbio Inc?
What is the 50-day moving average of Regenxbio Inc?
How many employess does Regenxbio Inc has?

Latest RGNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.